Family history and the risk of gastric cancer by Yaghoobi, M et al.
Minireview
Family history and the risk of gastric cancer
M Yaghoobi
1,2, R Bijarchi
3 and SA Narod*,2
1Department of Clinical and Metabolic Genetics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada;
2Women’s College Research
Institute, Women’s College Hospital and the University of Toronto, Toronto, Ontario, Canada;
3Division of Respirology, Department of Medicine,
St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada
Both environmental and genetic factors have a role in the aetiology of gastric cancer. The nature of the genetic factors has not been
well-studied and, outside of a few rare cancer syndromes, the genes involved have not been identified. Having a first-degree relative
with gastric cancer is a consistent risk factor for gastric cancer, although the magnitude of the odds ratio (OR) associated with a
positive family history varies with the ethnic group and with the geographic region. In published case–control studies, the odds ratio
varies from approximately 2 to 10, depending on the country. Unlike other common adult cancers, the risk of gastric cancer in
migrants is similar to that of the population of origin and does not approach that of the host population in the first generation post-
migration. It is hoped that molecular studies, including genomewide association studies (GWAS), will illuminate the genetic factors
underlying this important association.
British Journal of Cancer (2010) 102, 237–242. doi:10.1038/sj.bjc.6605380 www.bjcancer.com
Published online 3 November 2009
& 2010 Cancer Research UK
Keywords: gastric cancer; hereditary; polymorphism; familial
                                        
Gastric cancer is the fourth most common cancer worldwide and is
the second most frequent cause of death from cancer (Parkin,
2004). Each year, approximately 700000 people die of gastric
cancer, representing about 10% of all cancer deaths (Parkin et al,
2001). Gastric cancers have been subdivided on the basis of their
histological appearance into diffuse and intestinal types, and into
cardia and non-cardia sites on the basis of their location (Lauren,
1965). The diffuse type appears, on average, at an earlier age than
the intestinal type (Eto et al, 2006). It is believed that both
environmental and genetic factors have causative roles, and it is
possible that the risk factors are different for the various subtypes.
The most important environmental risk factor is infection with
Helicobacter Pylori, in particular for the non-cardia type of gastric
cancer (Helicobacter and Cancer Collaborative Group, 2001).
Suggested dietary risk factors include an increased intake of
nitrites, nitrosamines and of salted foods and a low intake of fruits
and vegetables (Jakszyn and Gonza ´lez, 2006; Tsugane and
Sasazuki, 2007). Smoking is also a risk factor (Neugut et al,
1996). The roles of familial and genetic factors have not been well-
studied. Approaches to the study of genetic factors include case–
control studies, molecular studies of cancer susceptibility and
family-based studies. The key studies in the field are reviewed
below.
WORLDWIDE DISTRIBUTION OF GASTRIC CANCER
The international distribution of gastric cancer differs markedly
from that of most other common adult tumours (e.g., breast,
prostate and colon) in that the worldwide trend in incidence does
not seem to parallel trends in westernization; that is, the rates
across populations do not seem to be associated with increasing
BMI, with a high-fat diet or with a sedentary lifestyle. In most
western countries, the risk of (non-cardia) gastric cancer has
declined steadily over the past 50 years, but the risk of cardia
gastric cancer is stable, or is rising. In addition, the regional
variation in the incidence of gastric cancer is also remarkable,
which is much more pronounced than that of other common
cancers; for example, in China, the annual adjusted rate is 20 per
100000 for men in Beijing, compared with 145 for men in the
Changle province (Cancer Incidence in Five Continents, 2002).
Again, within a given geographic region, there is marked variation
according to the ethnic group – this is not observed to the same
extent for other common cancers. For example, in Los Angeles, the
rates of stomach cancer vary from 7 to 43 per 100000 per year by
ethnic group, whereas, in the same city, the ethnic-specific rates
for colon cancer vary modestly – from 17 to 28 per 100000 per year
(Table 1 and Figure 1) (Cancer Incidence in Five Continents, 2002).
The reason for the extensive variation is unknown, and may
include environmental exposures, but is also consistent with an
important genetic contribution (however, the decline in incidence
in western populations argues against a purely genetic aetiology –
likely both factors will prove to be important).
FAMILIAL RISK
Familial relative risk is a hallmark of genetic susceptibility.
Theoretically, familial clustering may also be because of non-
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www.bjcancer.comhereditary factors, such as exposure to H. Pylori, smoking or to a
common diet. It is also possible that a gene/environment
interaction is involved – this would be the case when genetic
susceptibility to infection or to the mutagenic effects of smoking
(or another carcinogen) were responsible for the observed familial
association.
The importance of family history as a risk factor for
gastric cancer is most readily evaluated using the case–
control approach. We reviewed 15 case–control studies of
family history and gastric cancer (Table 2); six studies were from
Europe, seven from East Asia, one from India and one from the
United States. In these studies, the odds ratios (OR) of gastric
cancer were calculated with reference to one or more first- or
second-degree relatives with gastric cancer, but the definition of a
positive family history varied between studies. Most studies
combined all first-degree relatives (i.e., siblings and parents) but
one study published results separately for siblings and parents
(Bakir et al, 2000, 2003).
Dhillon et al (2001) studied 695 cases and 629 population-based
controls from the United States and estimated the familial relative
risk for gastric cancer to be 2.2 (95% CI 1.5–3.3). They adjusted for
age, gender, smoking, alcohol intake, BMI and household income,
but not for H. pylori infection. The risk was stronger for
individuals reporting two or more relatives with gastric cancer
(OR¼12.1; 95% CI 1.4–108).
Seven European studies were reviewed, two each from Turkey
and Italy and one each from Poland, Germany and Spain.
In a population-based case–control study of 464 gastric cancer
patients and 480 controls from Warsaw, Poland, a three-fold
increase in risk was associated with a history of gastric cancer in a
first-degree relative (OR¼3.5; 95% Cl 2.0–6.2) (see Lissowska
et al, 1999). No excess risk was observed with any other form
of cancer.
In the large Turkish study, the results for siblings were
published in 2000 (see Bakir et al, 2000) and the results for
parents were published in 2003 (see Bakir et al, 2003). This large
study included 1240 cases of gastric cancer and 1240 hospital-
based non-cancer controls. In that study, 14% of the cases reported
a sibling with gastric cancer (168 out of 1240) and 12% of the cases
reported a parent with gastric cancer (148 out of 1240). The
corresponding OR were 10.1 for siblings (95% CI 6.1–16.8) and 6.6
for parents (95% CI 4.2–10.4). The results were not adjusted for
other environmental factors.
In Italy, Palli et al (2001) estimated the OR to be 1.8 (95% CI
1.6–2.0), based on 126 cases of gastric cancer and 561 community-
based healthy controls. La Vecchia et al (1992) also studied Italian
Table 1 Rates of stomach and colon cancer in Los Angeles (males, per
100000 per year)
Stomach Colon Ratio
Non-Hispanic white 7.3 24.5 0.30
Hispanic white 14.4 21.0 0.69
Black 11.1 29.6 0.38
Chinese 14.5 19.9 0.73
Filipino 7.4 17.2 0.43
Japanese 21.8 27.7 0.79
Korean 43.4 20.0 2.17
Source: Cancer incidence in Five Continents, volume VIII.
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Figure 1 The ratio of gastric cancer to colon cancer in selected
countries.
Table 2 Case–control studies of gastric cancer and family history
Case group Control group
Study Country Family history nN nN RR (95% CI)
(Lissowska et al, 1999) Poland First-degree relative 464 480 3.5 (2.0–6.2)
(Brenner et al, 2000) Germany 10 68 (15%) 12 239 2.9 (1.3–6.5)
(La Vecchia et al, 1992) Italy First-degree relatives 79 628 (13%) 87 1776 2.6 (1.9–3.4)
(Palli et al, 2001) Italy First-degree relatives 40 126 (32%) 74 561 1.8 (1.6–2.0)
(Garcı ´a-Gonza ´lez et al, 2007) Spain One first-degree or two
second-degree relatives
51 290 (18%) 17 286 3.0 (1.8–5.0)
(Bakir et al, 2000) Turkey Siblings 168 1240 (14%) 19 1240 10.1 (6.1–16.8
(Bakir et al, 2003) Turkey Parents 148 1240 (12%) 25 1240 6.6 (4.2–10.4)
(Dhillon et al, 2001) USA First-degree relative 70 629 (11%) 35 695 2.2 (1.5–3.3)
(Gajalakshmi and Shanta, 1996) India Undefined 12 388 (3.5%) 2 388 5.7 (1.3–26)
(Minami and Tateno, 2003) Japan First-degree relatives 140 614 (23%) 369 2444 1.5 (1.3–1.8)
(Huang et al, 1999) Japan First-degree relatives 207 887 (23%) 3608 28619 1.9 (1.6–2.1)
(Ikeguchi et al, 2001) Japan First-, second- and
third-degree relatives
216 926 (23%) 254 2025 1.9 (1.6–2.2)
(Nagase et al, 1996) Japan 49 136 (365) 28 136 2.7 (1.7–4.4)
(Eto et al, 2006) Japan First-degree relative 543 1400 (39%) 1475 13467 3.5 (3.3–3.8)
(Hong et al, 2006) Korea First-degree relatives 94 108 (87%) 21 238 9.9 (6.5–15)
(Chen et al, 2004) Taiwan First-degree relatives 47 176 (27%) 54 579 2.5 (1.3–4.8)
Family history and the risk of gastric cancer
M Yaghoobi et al
238
British Journal of Cancer (2010) 102(2), 237–242 & 2010 Cancer Research UKpatients, and estimated the familial relative risk to be 2.6 (95% CI
1.9–3.4), based on 628 cases and 1776 hospital-based controls.
A small study from Germany (Brenner et al, 2000) showed a
relative risk of 2.9 (95% CI 1.3–6.5). In this study, Brenner et al
showed that a family history of gastric cancer was also associated
with an increased prevalence of H. pylori infection. Individuals
with both H. pylori infection and a positive family history of
gastric cancer faced an eight-fold increased risk of development of
gastric cancer, compared with people with neither risk factor.
However, after adjustment for H pylori, the OR for the
development of gastric cancer, given a positive family history,
was 2.8, indicating that the familial and infectious risk factors are
independent.
A study from Spain with 404 cases and 404 controls reported an
OR of 3.4 (OR¼3.4; 95% CI 1.9–6.0) (Garcı ´a-Gonza ´lez et al, 2007).
In general, the rates of gastric cancer in Asia are higher than the
rates in Europe or North America, but there is marked variation
within the continent. The highest reported rates are from Japan
and Korea; in these countries, the rates are typically about 70 per
100000 per year (Cancer Incidence in Five Continents, 2002). In
contrast, India has one of the lowest reported rates (Cancer
Incidence in Five Continents, 2002). Of the eight identified case–
control studies from Asia, the highest reported OR was from Korea
(RR¼9.9; 95% CI 6.5–15), but this study was relatively small (238
cases and 108 hospital-based controls) (Hong et al, 2006).
Remarkably, 94 of 108 Korean patients (87%) with gastric cancer
reported a first-degree relative with gastric cancer – this is a much
higher proportion than has been reported elsewhere.
Five studies from different regions of Japan reported OR ranging
from 1.5 to 3.5. The highest OR was reported by Eto et al (2006).
The OR was 3.5 (95% CI 3.3–3.8) after adjustment for age and
gender. In this study, the overall OR were similar for the intestinal
and diffuse subtypes, but among patients diagnosed with gastric
cancer before age 43, the OR for a family history with the intestinal
type was 12.5 (95% CI 4.8–32). The lowest reported OR in Japan
was 1.5 (95% CI 1.2–1.8), based on a large study on 614 cases and
2444 hospital-based controls by Minami et al (2003). Ikeguchi et al
(2001) studied 2025 cases of gastric cancer and 926 hospital-based
controls. The familial OR was approximately 2 (RR¼1.9; 1.6–2.2).
In this study, 14 of the 926 cases (1.5%) were from a family with
four or more cases of gastric cancer, suggesting that a dominant
gene may be responsible for a small proportion of cases. Huang
et al (1999) studied 887 cases and 28619 non-gastric cancer
controls. They also estimated the OR to be 1.9 (95% CI 1.6–2.1).
The OR was adjusted for age, sex, smoking, alcohol, consumption
of salty foods, and fruit and vegetable intake. Nagase et al (1996)
studied 136 cases and 136 controls and reported a crude OR of 2.7
(95% CI 1.7–4.4). In this study, family history was a stronger risk
factor for females than for males (OR¼4.5 for females and 1.2 for
males).
Chen et al (2004) studied 176 cases of cancer of the gastric
cardia and 579 hospital-based controls from Taiwan. They
reported a relative risk of 2.5 (95% CI 1.3–4.8), after adjusting
for age, sex, ethnicity, education, BMI, marital status and
socioeconomic status. It is not known whether the cancers in the
affected relatives were also in the gastric cardia.
A study from India included 388 cases and 388 non-gastric
cancer controls. The OR was 5.7 (95% CI 1.3–26) (Gajalakshmi
and Shanta, 1996), but this was based on a small number of
familial cases (n¼12) and controls (n¼2).
In summary, the case–control studies reviewed in this study
consistently report that a family history of gastric cancer is a risk
factor for gastric cancer. There were no negative studies. In the
majority of studies, the risk ratio was between 1.5-fold and
3.5-fold, but studies from Korea, Turkey and India reported
higher OR.
It is possible that familial clustering of non-genetic risk factors,
such as H Pylori infection or a diet high in salty foods and/or low
in fruit and vegetables, could contribute to familial clustering.
However, in the studies that adjusted for one or more of these risk
factors, the adjustment did not attenuate the relative risk
associated with a positive family history. This argues in favour
of genetic susceptibility underlying the observed familial cluster-
ing. The relevant genes are so far unknown.
A correlation between the national incidence rate and the
familial relative risk could be because of international variation in
the prevalence of one or more alleles of a susceptibility gene. It is
of interest that of the three countries with the highest reported
familial relative risks, one (Korea) has a very high incidence of
gastric cancer, one (India) has a low incidence of gastric cancer)
and one (Turkey) has an intermediate rate (Table 3).
Furthermore, even when the relative risk of gastric cancer were
found to be elevated to a similar extent for first-degree relatives of
the patients in the different studies, the actual risk to relatives will
depend on the baseline rate, which in turn depends on the ethnic
group and the country of residence. For example, the lifetime risk
of gastric cancer is approximately 1% in Canada and the United
States, but in much of Japan, the lifetime risk of gastric cancer in
men exceeds 10%. In Canada, a male with a first-degree relative
with gastric cancer, given a relative risk of 2.9, will face a lifetime
risk of about 3% (Cancer Incidence in Five Continents, 2002). In
contrast, when a relative risk of 2.9 is applied to relatives of
patients in Japan, the lifetime risk may approach 30%. In the
studies reviewed here, the countries with the highest familial
relative risks were Turkey, India and Korea, whereas the countries
with the highest baseline risks were Japan and Korea. Other
countries with high incidences of gastric cancer include Colombia,
Costa Rica, Russia, Belarus and the Baltic Republics (Lithuania,
Latvia and Estonia) (Table 3). To our knowledge, case–control
studies have not been conducted in Latin America or in Eastern
Europe.
GASTRIC CANCER SYNDROMES
Gastric cancer is an infrequent component of several inherited
cancer predisposition syndromes, including hereditary non-
polyposis colon cancer, familial adenomatous polyposis and
Table 3 Estimated rates of gastric cancer and colon cancer in selected
countries
Age-standardised rate (males)
per 100000 per year
Country Gastric Colon
United States (SEER, white) 6.6 25.5
Canada 9.1 25.9
United Kingdom 13.1 20.6
France (Calvados) 12.2 22.3
Germany (Saarland) 14.7 27.3
Russia (St Petersburg) 38.3 19.9
Poland (Silesia) 22.9 15.6
Estonia 31.9 16.1
Latvia 28.2 12.5
Lithuania 29.7 11.8
Belarus 40.5 11.1
Turkey 12.2
Japan (Osaka) 59.9 22.1
Korea (Seoul) 68.0 13.1
China (Beijing) 19.8 7.2
India (Mumbai) 6.3 3.4
Colombia 18.8 10.4
Costa rica 40.1 7.1
Brazil 21.2 11.3
Source: Cancer Incidence in Five Continents, Globocan.
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1992; Watson and Lynch, 1993; Lynch and Smyrk, 1996).
Hereditary diffuse gastric cancer (HDGC) is a rare, autosomal
dominant inherited form of gastric cancer. Germline CDH1
mutations were first described in three New Zealand families with
early-onset, poorly differentiated, high-grade, diffuse gastric
cancer (Guilford et al, 1998). In a recent international study of
38 families with HDGC, 15 CDH1 mutations were found,
representing 39% of the families tested (Kaurah et al, 2007). The
penetrance for gastric cancer among individuals with a CDH1
mutation is estimated to be about 40%. However, considering the
rarity of the syndrome, CDH1 mutations make a small contribu-
tion to the total burden of familial gastric cancer.
The genetic abnormalities that predispose to gastric cancer seem
not to be the same in all countries – possibly because of different
frequencies of the predisposing mutations or the need for
environmental co-factors. There are several examples. Gastric
cancer is not a classical component of the breast–ovarian cancer
syndrome, but in Poland, BRCA2 germline mutations were
identified in 21% of families with both gastric and breast cancer
(Jakubowska et al, 2002). In Japan, gastric cancer is an expression
of familial polyposis coli, whereas in North America, colon cancers
are dominant (Shimoyama et al, 2004). Similarly, gastric cancer is
not a central component of the Li-Fraumeni syndrome in North
America, but germline mutations in p53 have been reported in
three gastric cancer families from Japan (Yamada et al, 2007). Two
other studies searched for germline p53 mutations in 31 gastric
cancer families from Portugal and in 35 gastric cancer families
from Germany. One germline p53 mutation was found in each of
these series (Keller et al, 2004; Oliveira et al, 2004).
Carriers of germline mutations in the mismatch repair (MMR)
genes, MSH2 and MLH1, also have an increased risk of gastric
cancer (Imai and Yamamoto, 2008). Typically, germline mutations
in the MMR genes are the cause of hereditary non-polyposis colon
cancer (HNPCC), but somatic (i.e., cancer specific) mutations in
these genes are also common in non-familial cases of colon cancer.
Germline or somatic mutations in mismatch repair genes usually
result in the presence of microsatellite instability (MSI) in the
colon tumour tissue. Although MSI is present in 20 to 30% of cases
of gastric cancer (Renault et al, 1996), germline or somatic
mutations in the mismatch repair genes are rarely observed in
MSI-positive cases (Keller et al, 1996). In one study, MSI was
significantly associated with antral tumours of the stomach and a
positive family history of gastric cancer (Ottini et al, 1997).
POLYMORPHIC VARIANTS
Currently, there is much interest in the identification of low-
penetrance alleles that are associated with an increased risk for
common forms of cancer. It is believed that for many adult
cancers, familial aggregation may be more the result of a number
of low-penetrant alleles acting in combination, rather than one or a
few highly penetrant dominant cancer genes. Until recently, gastric
cancer has not been well-studied in this regard, but over the past
few years, several investigators have begun to evaluate candidate
genes. Genes have been selected either because they are believed
to influence susceptibility to H. Pylori infection, to limit
the production of gastric acid, or moderate local inflammation
or influence the metabolism of potential carcinogens. To date,
no consistent association has emerged and only a few of the key
studies are reviewed here.
A series of studies has been conducted on a sample of Polish
gastric patients and controls; these focus largely on the cytokines
and related proteins that are believed to be involved in
inflammatory processes. Interleukin 1B (IL1B) is pro-inflamma-
tory and is an inhibitor of gastric acid secretion. El-Omar et al
studied a non-coding polymorphism in IL1B; they found that
individuals who carried two T alleles at this locus faced a 2.6-fold
increase in the risk of gastric cancer (95% CI 1.7–3.9) (El-Omar
et al, 2000). A related gene (IL1RN) from the same chromosome
region is also polymorphic; the researchers reported a 3.7-fold risk
(95% CI 2.4–5.7) associated with a specific genotype of a VNTR
polymorphism in the gene (El-Omar et al, 2000). A polymorphic
variant in the promoter of mannose-binding lectin-2 was also
associated with a 1.8-fold increase in the risk of gastric cancer in
Poland (95% CI 1.1–2.9) (Baccarelli et al, 2006).
In a study of gastric cancer patients from Mexico, the IL10-592
CC genotype was associated with an OR of 2.2 (95% CI 1.0–4.6) for
intestinal-type gastric cancer (Sicinschi et al, 2006). A later Spanish
study, which included most of these cytokine variants, did not
confirm the reported associations (Garcı ´a-Gonza ´lez et al, 2007).
Wang et al conducted a meta-analysis of 39 studies, which
included 6863 cases and 8434 controls (Wang et al, 2007). The
summary OR of gastric cancer risk associated with the IL-1B-511T
polymorphism was 1.26 (95% CI 1.03–1.55) and the summary OR
associated with the IL-1RN*2 allele was 1.20 (95% CI 1.01–1.41).
The IL-1B-511T polymorphism was associated with an increased
risk of gastric cancer of the intestinal type (OR¼1.76, 95% CI
1.12–2.57). The IL-1RN*2 variant was associated with an
increased risk of gastric cancer among Caucasians (OR¼1.30,
95% CI 1.09–1.54).
In summary, the studies to date in aggregate do not support the
hypothesis that familial aggregation of gastric cancer can be
accounted for by low-penetrance polymorphic variants. However,
association studies to date have been small and few ethnic groups
have been represented. It is possible that the susceptibility variants
are different for different populations, due to variability in
modifier genes or environmental factors. It is therefore important
that large-scale international studies and/or meta-analyses be
conducted to see whether there are consistent genetic associations
or whether ethnic-specific effects are present. It is expected that
these will soon be extended to include genomewide association
studies (GWAS).
SCREENING AND PREVENTION
It is hoped that the identification of genetic factors for gastric
cancer will lead to the development of a clinical test that can be
used to identify individuals at high risk. This classification may
allow us to focus preventive efforts and screening programs on
individuals at high risk. The exact means of prevention may
depend on the susceptibility gene involved (and the molecular
pathway to be targeted). It may be that different genes operate in
different high-risk populations.
Aspirin use has been associated with a modest reduction in the
risk of gastric cancer. The use of aspirin (HR, 95% CI 0.64, 0.47–
0.86) or other NSAIDs (0.68, 0.51–0.92) was associated with a
significantly lower risk of gastric non-cardia cancer (Abnet et al,
2009). It is important to ask whether proton pump inhibitors,
which are prescribed to reduce gastric acid protection, can
potentially be used for chemoprevention of gastric cancer in
high-risk individuals.
It is hoped that the eradication of H Pylori infection through
antibiotic therapy will reduce the incidence of gastric cancer.
A randomised trial of antibiotic therapy was conducted in a cohort
of patients with resectable gastric cancer, with the aim of
preventing second primary cancers (Fukase et al, 2008). After 3
years of follow-up, a second gastric carcinoma developed in nine
patients in the treatment arm and in 24 patients in the control
group (OR¼0.35, 95% CI 0.16–0.78; P¼0.009). It may be that in
high-risk areas all residents should be screened for H. Pylori
infection and offered eradication therapy. However, in low-risk
areas, therapy might be targeted to high-risk individuals, such as
those who are genetically predisposed.
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(Lynch et al, 2008), genetic markers cannot be used to identify
individuals at high risk of gastric cancer. Similarly, preventive
surgery is limited to those with a mutation in E-cadherin, which
predisposes to hereditary diffuse gastric cancer (Lynch et al, 2008).
The risk of gastric cancer for an individual can be estimated on the
basis of family history, sex and place of residence. Currently,
endoscopy screening is recommended only in high-risk areas such
as Japan, and is based on residence and ethnic group rather than
family history. It is possible that in the future, endoscopy might be
offered to individuals in other countries who are determined to be
at high risk, based on genetic markers.
CONCLUSION
A positive family history is a strong and consistently reported risk
factor for gastric cancer, but the molecular basis for the familial
aggregation is largely unknown. The known cancer syndromes do
not account for a large part of the familial clustering. Unlike the
situation for other common cancers, guidelines have not been
developed for the assessment of the family history of individuals
with gastric cancer. A recent systematic review of clinical patterns
of genetic assessment and referral for 11 different types of
cancer in the United Kingdom did not include gastric cancer
(Featherstone et al, 2007). To some extent, this lack of attention
may be because of the international distribution of gastric
cancer cases; that is, high rates in Asia, Eastern Europe and Latin
America, but relatively low rates in North America and
Europe. There may also be a lack of awareness of the extent to
which gastric cancer is familial. In most studies, the familial
relative risk is approximately three-fold, which is larger than that
observed for most other adult forms of solid cancer, with the
exception of ovarian cancer. In India, Korea and Turkey, much
higher relative risks have been reported. It will be important to
confirm these results and to conduct studies in other regions of
high incidence. Molecular epidemiology studies, such as GWAS,
may prove to be useful in identifying the genetic factors
responsible.
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